GlassScriptPhysician profile
John E Marx
NPI 1720491731
$4,406.24
in general payments reported to CMS, 2019-2025
30 companies · $534 in 2025
The $534 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $673 · 2020: $309 · 2021: $505 · 2022: $859 · 2023: $557 · 2024: $970 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,061.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,060.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $615.24 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $607.47 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $555.41 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $504.37 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $396.75 | 2019-2025 | |
| Amgen INC. | $208.45 | 2019-2023 | Evenity |
| Astellas Pharma US INC | $187.02 | 2023-2025 | Veozah |
| Axsome Therapeutics, INC. | $183.37 | 2024-2025 | Auvelity |
| Glaxosmithkline, LLC. | $147.44 | 2020-2025 | Trelegy Ellipta |
| Idorsia Pharmaceuticals US INC | $135.97 | 2024 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.72 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $110.36 | 2021-2025 | |
| Abbott Laboratories | $98.97 | 2019-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.83 | 2019-2025 | Xifaxan |
| Exact Sciences Corporation | $60.01 | 2023-2024 | Cologuard Collection Kit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $53.60 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $50.93 | 2019-2020 | |
| Amarin Pharma, INC. | $41.57 | 2019 | |
| Ironwood Pharmaceuticals, INC | $38.27 | 2019-2023 | Linzess |
| Merck Sharp & Dohme LLC | $36.99 | 2022-2024 | M-M-R II, Gardasil, Gardasil 9 |
| E.R. Squibb & Sons, L.L.C. | $30.36 | 2023-2024 | Eliquis |
| Daiichi Sankyo INC. | $19.06 | 2019 | |
| Vanda Pharmaceuticals INC. | $16.50 | 2025 | Hetlioz, Fanapt |
| Genentech USA, INC. | $15.92 | 2019 | |
| Allergan, INC. | $14.69 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $13.68 | 2023 | Rexulti |
| Lundbeck LLC | $13.46 | 2025 | Rexulti |
| Gilead Sciences, INC. | $13.45 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.36 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Marx listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.